)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Evonile Pharma
Evonile Pharma (500672) investor relations material
Evonile Pharma Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary4 Nov, 2026
Executive summary
Q2 marked the shift from a single-customer model to direct sales through an independent distribution and commercial platform; transition costs and lower sales weighed on results.
Q2 revenue was ₹56.05 crore and net loss was ₹77.54 crore, including ₹68.26 crore of exceptional charges and other non-recurring costs.
Priorities include completing the organizational build-out, restoring portfolio growth, establishing the appropriate cost base and reducing debt.
Financial highlights
Q2 FY27 revenue from operations was ₹56.05 crore vs ₹90.33 crore, down 38% YoY; H1 revenue was ₹159.86 crore vs ₹177.88 crore, down 10%.
Adjusted operating EBITDA was a ₹16.4 crore loss in Q2 vs ₹23.9 crore income; H1 was ₹18.5 crore income vs ₹51.1 crore. Operating EBITDA was a ₹31.8 crore Q2 loss and ₹3.1 crore H1 income.
Q2 net loss was ₹77.54 crore vs net profit of ₹24.22 crore; H1 net loss was ₹45.33 crore vs net profit of ₹51.84 crore.
H1 cost of goods sold rose 6% to ₹102.8 crore and employee expenses rose 80% to ₹19.1 crore; other expenses increased 3% to ₹19.5 crore.
Q2 employee costs rose to ₹14 crore from ₹5 crore as the field force and corporate team were built; other expenses were ₹11 crore, nearly flat YoY excluding one-offs.
Outlook and guidance
Full field-force build-out is targeted by Q4 FY27, with about 900 representatives planned, including ~300 for Minipress XL; employee and selling costs are expected to rise through H2.
Full-portfolio revenue should begin reflecting from Q3; Q4 FY27 or Q1 FY28 is expected to show a stable annualized base, with quarterly revenue near ₹150 crore and annual revenue near ₹600 crore.
Organic ambition is to double the stabilized base over five to six years; new products are expected from late Q4 or Q1 FY28 through brand extensions and products for existing specialist teams.
A further ₹15 crore–₹20 crore of one-time costs may arise in Q3; costs are expected to stabilize by Q4. Finance costs are guided at up to ₹15 crore in Q3 and ₹10 crore–₹15 crore in Q4.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Evonile Pharma
- H1 profit rose YoY despite weaker Q2 revenue and a 54.0 million tax-litigation provision.500672
Q2 24/25 - Q1 profit rose to ₹257.4 million as revenue reached ₹922.9 million.500672Q1 24/25
- Q3 revenue grew YoY, while profit declined; 9M net profit edged higher.500672Q3 24/25
- FY25 profit and EPS rose despite lower revenue; INR25/share dividend recommended.500672Q4 24/25
- Q1 profit rose YoY despite lower revenue; cost auditor appointment awaits shareholder ratification.500672Q1 25/26
- Q2 profit rose YoY; H1 profit advanced despite lower revenue.500672Q2 25/26
- Q3 revenue and profit fell YoY as Labour Code costs and tax adjustments shaped results.500672Q3 25/26
- FY26 profit declined; a proposed 70.68% stake sale awaits approvals.500672Q4 25/26
- Q1 revenue and profit rose YoY as a proposed 70.68% ownership transfer advanced.500672Q1 26/27
Next Evonile Pharma earnings date
Q3 26/2727 Jan, 2027
Evonile Pharma
Next Evonile Pharma earnings date
Q3 26/2727 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)